Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S.A.’s 7,478,261 American Depositary Shares. Aggregate gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the company, were approximately $107.7 million. Inventiva’s ADSs are listed on the Nasdaq Global Market under the symbol “IVA” and its ordinary shares are listed on Euronext Paris under the symbol “IVA.”
Headquartered in Daix, France, Inventiva S.A. is clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS and other diseases with significant unmet medical need.
The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Eryn E. Gordon and Roman Shapurko. Partner Jacques Naquet-Radiguet and associate Stéphane Daniel provided advice on matters of French law. Partner David R. Bauer and associates Michael V. Policastro and S. Dream Montgomery provided intellectual property advice. The tax team included partner William A. Curran. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and Paris offices.